ProFuse: Radiology & Urology Synergy In Prostate Cancer Detection
Friday, April 20, 2012
Eigen has received 510(k) clearance for its ProFuse multi-modality image fusion software for the radiology lab. Additionally, ProFuse Bx is now available as an optional add-on to Artemis, Eigen’s 3D ultrasound-guided prostate biopsy platform. The ProFuse line creates a synergy between the radiology lab and urology suite such that patients can benefit from this convergence.
This fusion of MRI and ultrasound is a time-conscious and cost-effective alternative to in-bore biopsies. In relation to prostate cancer detection, multi-parametric MRI (mpMRI) has been shown to have greater sensitivity and specificity compared to traditional screening methods such as PSA. Using ProFuse to initially evaluate MRI images, radiologists can provide accurate mapping data about abnormalities which can then be confirmed during a biopsy. During biopsy in the urology suite, Artemis with ProFuse Bx helps target the suspected lesions (identified in ProFuse) using its real-time ultrasound guidance.
Eigen president Dr. Mahtab Damda commented, “This is an exciting time for Eigen. With the FDA clearance of our ProFuse and ProFuse Bx, the benefits of MRI imaging can be used to guide prostate biopsies in an office setting. Eigen has always strived to produce high quality products and solutions; ProFuse and ProFuse Bx are additional innovative products that can significantly change how prostate cancer is diagnosed.”
ProFuse guidance has been tested in a research setting at UCLA for over two years with significant positive outcomes. Other sites are also currently using Artemis with ProFuse Bx under research protocols.
Targeted Prostate Biopsy Using
Wednesday May 11, 2011
A new UCLA research study aims to redefine prostate cancer significance through advanced clinical validation of Artemis, Eigen's imaging device that allows 3D prostate visualization and tracking. By fusing multi-parametric MRI (T2-weighted, diffusion-weighted imaging, dynamic contrast enhancement) with real-time ultrasound, suspicious areas seen on the MRI can be tracked and targeted during prostate biopsy. This research aims to improve currently available methods of cancer diagnosis.
The Smilow Comprehensive Prostate Cancer Center Installs Artemis
Thursday, February 24, 2011
As a world leader in the advancement of the detection and treatment of prostate cancer, the Smilow Comprehensive Prostate Cancer Center at NYU Langone Medical Center is the first medical facility in the Northeast to install Artemis, an innovative image guidance and navigation system for prostate biopsy.
“We are very excited about Artemis,” says Herbert Lepor, MD, Director of the Smilow Comprehensive Prostate Cancer Center. “No major advances have been made in the TRUS/biopsy technique over the past 20 years, except for use of local anesthesia and a 12-core approach. This new device helps the Smilow Center provide the most sophisticated level of prostate diagnosis possible and assists our physicians in providing even better prostate cancer treatment and management, especially for men electing active surveillance and focal therapy.”
Read the complete story here.
ABC 7 Chicago's Healthbeat
Thursday, April 15, 2010
Eigen's Artemis system is featured as a part of NorthShore University HealthSystem's active surveillance program. The system, which converts the doctor's current 2D ultrasound to a 3D image, is used for its precision needle guidance, planning capabilities, and for repeat biopsies.
"We get a lot more information with this, so we have increased our data significantly. That should translate into better patient care," says Urologist Dr. Michael McGuire, NorthShore University HealthSystem.
View the entire Healthbeat news segment here (3:38).
Friday, May 09, 2008
See what physicians are saying about Artemis. Watch the KCBI-TV newscast.